Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Long-term use of pitolisant to treat patients with narcolepsy: Harmony III Study.

Dauvilliers Y, Arnulf I, Szakacs Z, Leu-Semenescu S, Lecomte I, Scart-Gres C, Lecomte JM, Schwartz JC; HARMONY III study group .

Sleep. 2019 Oct 21;42(11). pii: zsz174. doi: 10.1093/sleep/zsz174.

2.

Bioavailability and Cardiovascular Effects of Adrenaline Administered by Anapen Autoinjector in Healthy Volunteers.

Duvauchelle T, Robert P, Donazzolo Y, Loyau S, Orlandini B, Lehert P, Lecomte JM, Schwartz JC.

J Allergy Clin Immunol Pract. 2018 Jul - Aug;6(4):1257-1263. doi: 10.1016/j.jaip.2017.09.021. Epub 2017 Nov 3.

3.

Nonclinical cardiovascular safety of pitolisant: comparing International Conference on Harmonization S7B and Comprehensive in vitro Pro-arrhythmia Assay initiative studies.

Ligneau X, Shah RR, Berrebi-Bertrand I, Mirams GR, Robert P, Landais L, Maison-Blanche P, Faivre JF, Lecomte JM, Schwartz JC.

Br J Pharmacol. 2017 Dec;174(23):4449-4463. doi: 10.1111/bph.14047. Epub 2017 Oct 19.

4.

Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial.

Szakacs Z, Dauvilliers Y, Mikhaylov V, Poverennova I, Krylov S, Jankovic S, Sonka K, Lehert P, Lecomte I, Lecomte JM, Schwartz JC; HARMONY-CTP study group.

Lancet Neurol. 2017 Mar;16(3):200-207. doi: 10.1016/S1474-4422(16)30333-7. Epub 2017 Jan 25.

PMID:
28129985
5.

Synthesis and evaluation of a 2-benzothiazolylphenylmethyl ether class of histamine H4 receptor antagonists.

Labeeuw O, Levoin N, Billot X, Danvy D, Calmels T, Krief S, Ligneau X, Berrebi-Bertrand I, Robert P, Lecomte JM, Schwartz JC, Capet M.

Bioorg Med Chem Lett. 2016 Nov 1;26(21):5263-5266. doi: 10.1016/j.bmcl.2016.09.049. Epub 2016 Sep 19.

PMID:
27692832
6.

Discovery of nanomolar ligands with novel scaffolds for the histamine H4 receptor by virtual screening.

Levoin N, Labeeuw O, Billot X, Calmels T, Danvy D, Krief S, Berrebi-Bertrand I, Lecomte JM, Schwartz JC, Capet M.

Eur J Med Chem. 2017 Jan 5;125:565-572. doi: 10.1016/j.ejmech.2016.09.074. Epub 2016 Sep 24.

PMID:
27718472
7.

Clinical trials with H3-receptor inverse agonists: What they tell us about the role of histamine in the human brain.

Schwartz JC, Lecomte JM.

Neuropharmacology. 2016 Jul;106:35-6. doi: 10.1016/j.neuropharm.2016.04.006. Epub 2016 Apr 7. No abstract available.

PMID:
27060410
8.

Improving selectivity of dopamine D3 receptor ligands.

Capet M, Calmels T, Levoin N, Danvy D, Berrebi-Bertrand I, Stark H, Schwartz JC, Lecomte JM.

Bioorg Med Chem Lett. 2016 Feb 1;26(3):885-888. doi: 10.1016/j.bmcl.2015.12.068. Epub 2015 Dec 21.

PMID:
26723530
9.

Time-dependent resonant scattering: an analytical approach.

Lecomte JM, Kirrander A, Jungen Ch.

J Chem Phys. 2013 Oct 28;139(16):164111. doi: 10.1063/1.4825335.

PMID:
24182008
10.

Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial.

Dauvilliers Y, Bassetti C, Lammers GJ, Arnulf I, Mayer G, Rodenbeck A, Lehert P, Ding CL, Lecomte JM, Schwartz JC; HARMONY I study group.

Lancet Neurol. 2013 Nov;12(11):1068-75. doi: 10.1016/S1474-4422(13)70225-4. Epub 2013 Oct 7.

PMID:
24107292
11.

Determination of the binding mode and interacting amino-acids for dibasic H3 receptor antagonists.

Levoin N, Labeeuw O, Krief S, Calmels T, Poupardin-Olivier O, Berrebi-Bertrand I, Lecomte JM, Schwartz JC, Capet M.

Bioorg Med Chem. 2013 Aug 1;21(15):4526-9. doi: 10.1016/j.bmc.2013.05.035. Epub 2013 Jun 2.

PMID:
23787288
12.

Novel and highly potent histamine H3 receptor ligands. Part 3: an alcohol function to improve the pharmacokinetic profile.

Labeeuw O, Levoin N, Poupardin-Olivier O, Calmels T, Ligneau X, Berrebi-Bertrand I, Robert P, Lecomte JM, Schwartz JC, Capet M.

Bioorg Med Chem Lett. 2013 May 1;23(9):2548-54. doi: 10.1016/j.bmcl.2013.02.118. Epub 2013 Mar 14.

PMID:
23535326
13.

Preclinical evaluation of the abuse potential of Pitolisant, a histamine H₃ receptor inverse agonist/antagonist compared with Modafinil.

Uguen M, Perrin D, Belliard S, Ligneau X, Beardsley PM, Lecomte JM, Schwartz JC.

Br J Pharmacol. 2013 Jun;169(3):632-44. doi: 10.1111/bph.12149.

14.

Novel and highly potent histamine H3 receptor ligands. Part 1: withdrawing of hERG activity.

Levoin N, Labeeuw O, Calmels T, Poupardin-Olivier O, Berrebi-Bertrand I, Lecomte JM, Schwartz JC, Capet M.

Bioorg Med Chem Lett. 2011 Sep 15;21(18):5378-83. doi: 10.1016/j.bmcl.2011.07.006. Epub 2011 Jul 13.

PMID:
21802950
15.

Novel and highly potent histamine H3 receptor ligands. Part 2: exploring the cyclohexylamine-based series.

Labeeuw O, Levoin N, Poupardin-Olivier O, Calmels T, Ligneau X, Berrebi-Bertrand I, Robert P, Lecomte JM, Schwartz JC, Capet M.

Bioorg Med Chem Lett. 2011 Sep 15;21(18):5384-8. doi: 10.1016/j.bmcl.2011.06.102. Epub 2011 Jun 28.

PMID:
21783360
16.

Homology Model Versus X-ray Structure in Receptor-based Drug Design: A Retrospective Analysis with the Dopamine D3 Receptor.

Levoin N, Calmels T, Krief S, Danvy D, Berrebi-Bertrand I, Lecomte JM, Schwartz JC, Capet M.

ACS Med Chem Lett. 2011 Feb 11;2(4):293-7. doi: 10.1021/ml100288q. eCollection 2011 Apr 14.

17.

Synthesis and evaluation of amides surrogates of dopamine D3 receptor ligands.

Jean M, Renault J, Levoin N, Danvy D, Calmels T, Berrebi-Bertrand I, Robert P, Schwartz JC, Lecomte JM, Uriac P, Capet M.

Bioorg Med Chem Lett. 2010 Sep 15;20(18):5376-9. doi: 10.1016/j.bmcl.2010.07.096. Epub 2010 Jul 29.

PMID:
20708933
18.

An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin-/- mice and patients.

Lin JS, Dauvilliers Y, Arnulf I, Bastuji H, Anaclet C, Parmentier R, Kocher L, Yanagisawa M, Lehert P, Ligneau X, Perrin D, Robert P, Roux M, Lecomte JM, Schwartz JC.

Neurobiol Dis. 2008 Apr;30(1):74-83. doi: 10.1016/j.nbd.2007.12.003. Epub 2007 Dec 27.

PMID:
18295497
19.

Pilot case study of the therapeutic potential of hyperbaric oxygen therapy on chronic brain injury.

Hardy P, Johnston KM, De Beaumont L, Montgomery DL, Lecomte JM, Soucy JP, Bourbonnais D, Lassonde M.

J Neurol Sci. 2007 Feb 15;253(1-2):94-105. Epub 2007 Jan 16.

PMID:
17234213
20.

BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: Preclinical pharmacology.

Ligneau X, Perrin D, Landais L, Camelin JC, Calmels TP, Berrebi-Bertrand I, Lecomte JM, Parmentier R, Anaclet C, Lin JS, Bertaina-Anglade V, la Rochelle CD, d'Aniello F, Rouleau A, Gbahou F, Arrang JM, Ganellin CR, Stark H, Schunack W, Schwartz JC.

J Pharmacol Exp Ther. 2007 Jan;320(1):365-75. Epub 2006 Sep 27.

PMID:
17005916
21.

Effect of hyperbaric oxygen on oxygen uptake and measurements in the blood and tissues in a normobaric environment.

Hodges AN, Delaney S, Lecomte JM, Lacroix VJ, Montgomery DL.

Br J Sports Med. 2003 Dec;37(6):516-20.

22.

Neuropsychological effects of hyperbaric oxygen therapy in cerebral palsy.

Hardy P, Collet JP, Goldberg J, Ducruet T, Vanasse M, Lambert J, Marois P, Amar M, Montgomery DL, Lecomte JM, Johnston KM, Lassonde M.

Dev Med Child Neurol. 2002 Jul;44(7):436-46.

23.

Efficacy and tolerability of racecadotril in acute diarrhea in children.

Cézard JP, Duhamel JF, Meyer M, Pharaon I, Bellaiche M, Maurage C, Ginies JL, Vaillant JM, Girardet JP, Lamireau T, Poujol A, Morali A, Sarles J, Olives JP, Whately-Smith C, Audrain S, Lecomte JM.

Gastroenterology. 2001 Mar;120(4):799-805.

PMID:
11231932
24.

Antihypertensive effects of fasidotril, a dual inhibitor of neprilysin and angiotensin-converting enzyme, in rats and humans.

Laurent S, Boutouyrie P, Azizi M, Marie C, Gros C, Schwartz JC, Lecomte JM, Bralet J.

Hypertension. 2000 May;35(5):1148-53.

PMID:
10818079
25.

An overview of clinical studies with racecadotril in adults.

Lecomte JM.

Int J Antimicrob Agents. 2000 Feb;14(1):81-7. Review.

PMID:
10717506
26.

Comparison of racecadotril and loperamide in children with acute diarrhoea.

Turck D, Berard H, Fretault N, Lecomte JM.

Aliment Pharmacol Ther. 1999 Dec;13 Suppl 6:27-32.

27.

Comparison of racecadotril and loperamide in adults with acute diarrhoea.

Vetel JM, Berard H, Fretault N, Lecomte JM.

Aliment Pharmacol Ther. 1999 Dec;13 Suppl 6:21-6.

28.

Racecadotril versus placebo in the treatment of acute diarrhoea in adults.

Hamza H, Ben Khalifa H, Baumer P, Berard H, Lecomte JM.

Aliment Pharmacol Ther. 1999 Dec;13 Suppl 6:15-9.

29.

Effects of racecadotril and loperamide on bacterial proliferation and on the central nervous system of the newborn gnotobiotic piglet.

Duval-Iflah Y, Berard H, Baumer P, Guillaume P, Raibaud P, Joulin Y, Lecomte JM.

Aliment Pharmacol Ther. 1999 Dec;13 Suppl 6:9-14.

30.

Racecadotril demonstrates intestinal antisecretory activity in vivo.

Primi MP, Bueno L, Baumer P, Berard H, Lecomte JM.

Aliment Pharmacol Ther. 1999 Dec;13 Suppl 6:3-7.

31.
32.
33.

A randomized controlled trial of the effect of naproxen on delayed onset muscle soreness and muscle strength.

Lecomte JM, Lacroix VJ, Montgomery DL.

Clin J Sport Med. 1998 Apr;8(2):82-7.

PMID:
9641434
34.

Acetorphan prevents cholera-toxin-induced water and electrolyte secretion in the human jejunum.

Hinterleitner TA, Petritsch W, Dimsity G, Berard H, Lecomte JM, Krejs GJ.

Eur J Gastroenterol Hepatol. 1997 Sep;9(9):887-91.

PMID:
9355788
35.

Bioavailability, antinociceptive and antiinflammatory properties of BP 2-94, a histamine H3 receptor agonist prodrug.

Rouleau A, Garbarg M, Ligneau X, Mantion C, Lavie P, Advenier C, Lecomte JM, Krause M, Stark H, Schunack W, Schwartz JC.

J Pharmacol Exp Ther. 1997 Jun;281(3):1085-94.

PMID:
9190840
36.

Treatment of refractory diarrhoea in AIDS with acetorphan and octreotide: a randomized crossover study.

Beaugerie L, Baumer P, Chaussade S, Berard H, Rozenbaum W, Pialoux G, Le Quintrec Y, Schwartz JC, Lecomte JM.

Eur J Gastroenterol Hepatol. 1996 May;8(5):485-9.

PMID:
8804878
38.

Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension.

Favrat B, Burnier M, Nussberger J, Lecomte JM, Brouard R, Waeber B, Brunner HR.

J Hypertens. 1995 Jul;13(7):797-804.

PMID:
7594444
40.

"Atriopeptidase" (EC 3.4.24.11) inhibition and protection of atrial natriuretic factor.

Gros C, Schwartz JC, Duhamel PL, Lecomte JM, Bralet J.

Adv Nephrol Necker Hosp. 1994;23:233-46. Review. No abstract available.

PMID:
8154356
41.
42.

The enkephalinase inhibitor, acetorphan, in acute diarrhoea. A double-blind, controlled clinical trial versus loperamide.

Roge J, Baumer P, Berard H, Schwartz JC, Lecomte JM.

Scand J Gastroenterol. 1993 Apr;28(4):352-4.

PMID:
8488368
43.
44.

Inhibition of neutral endopeptidase stimulates renal sodium excretion in patients with chronic renal failure.

Dussaule JC, Michel C, Peraldi MN, Lecomte JM, Gros C, Mignon F, Ardaillou R.

Clin Sci (Lond). 1993 Jan;84(1):31-9.

PMID:
8382131
45.

[Action of acetorphan, an enkephalinase inhibitor, in acute diarrhea].

Baumer P, Danquechin Dorval E, Bertrand J, Vetel JM, Schwartz JC, Lecomte JM.

Ann Gastroenterol Hepatol (Paris). 1992 Nov-Dec;28(6-7):279-85. French. No abstract available.

PMID:
1285638
46.

Effects of acetorphan, an enkephalinase inhibitor, on experimental and acute diarrhoea.

Baumer P, Danquechin Dorval E, Bertrand J, Vetel JM, Schwartz JC, Lecomte JM.

Gut. 1992 Jun;33(6):753-8.

47.

Effects of acetorphan, an antidiarrhoeal enkephalinase inhibitor, on oro-caecal and colonic transit times in healthy volunteers.

Bergmann JF, Chaussade S, Couturier D, Baumer P, Schwartz JC, Lecomte JM.

Aliment Pharmacol Ther. 1992 Jun;6(3):305-13.

PMID:
1350927
48.

Effect of neutral endopeptidase inhibitor on airway function and bronchial responsiveness in asthmatic subjects.

Nichol GM, O'Connor BJ, Lecomte JM, Chung KF, Barnes PJ.

Eur J Clin Pharmacol. 1992;42(5):491-4.

PMID:
1376694
49.

Mixed inhibitors of angiotensin-converting enzyme (EC 3.4.15.1) and enkephalinase (EC 3.4.24.11): rational design, properties, and potential cardiovascular applications of glycopril and alatriopril.

Gros C, Noël N, Souque A, Schwartz JC, Danvy D, Plaquevent JC, Duhamel L, Duhamel P, Lecomte JM, Bralet J.

Proc Natl Acad Sci U S A. 1991 May 15;88(10):4210-4.

50.

Comparison of acetorphan with clonidine for opiate withdrawal symptoms.

Hartmann F, Poirier MF, Bourdel MC, Loo H, Lecomte JM, Schwartz JC.

Am J Psychiatry. 1991 May;148(5):627-9.

PMID:
2018165

Supplemental Content

Loading ...
Support Center